Abstract
Vascular endothelial growth factor (VEGF) is a key mediator of endothelial cell proliferation, angiogenesis, and vascular permeability. Little is known about its expression in human pituitary adenomas.
We examined 148 human pituitary adenomas for VEGF protein expression by immunohistochemistry. The strongest immunoreactivity was present in GH adenomas, corticotroph, silent corticotroph, silent subtype 3, and nononcocytic null cell adenomas. GH adenomas treated with octreotide strained less intensely than did untreated tumors. Relatively weak staining was present in PRL, gonadotroph, thyrotroph, and oncocytic null cell adenomas in the same sections showed evidence of down-regulation of VEGF protein expression in adenomas. Pituitary carcinomas usually had stronger staining than adenomas.
In situ hybridization studies with oligonucleotide probes showed positive staining in all groups with stronger staining in GH, ACTH, TSH, and gonadotroph adenomas and in pituitary carcinomas.
These results indicate that VEGF expression is more prominent in certain adenoma subtypes, that decreased expression occurs in adenomas as compared to nontumorous pituitary and that carcinomas show increased VEGF expression relative to adenomas suggesting up-regulation of VEGF during pituitary tumor progression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36:127–137, 1995.
Ferrara N, Davis Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18:4–25, 1997.
Dvorak HF, Brown LF, Detmer M, Dvorak SM. Vascular permeability factor/vascular endothelial growth factor, microvascular permeability and angiogenesis. Am J Pathol 146:1029–1039, 1995.
Nicosia RF. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Commentary. Am J Pathol 153:11–16, 1998.
Folkman J. What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82:4–6, 1991.
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364, 1996.
Vidal S, Kovacs K, Cohen SM, Stefaneanu L, Lloyd RV, Scheithauer BW: Immunolocalization of vascular endothelial growth factor (VEGF) in nontumorous human pituitaries Endocr Pathol 10:109–112, 1999.
Scheithauer BW, Saso T, Kovacs K, Young WF, Ryan N, Randall RV. The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 65:461–474, 1990.
Lloyd RV, Scheithauer BW, Kovacs K, Roche PC. The immunophenotype of pituitary adenomas. Endocr Pathol 7:145–150, 1996.
Lloyd RV, Jin L, Qian X, Scheithauer BW, Young WF Jr, Davis DH. Analysis of the chromogranin A post-translational product pancreastatin and the prohormone convertases PC2 and PC3 in normal and neoplastic human pituitaries. Am J Pathol 146:1188–1198, 1995.
Berkman RA, Merrill MJ, Reinhold WC, Munacci WT, Saxena A, Clark WC, Robertson JT, Ali IU, Oldfield EH. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasm. J Clin Invest 91:153–159, 1993.
Fan L, Iseki E. Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch Histol Cytol 61:17–28, 1998.
Jabbour HN, Boddy SC, Lincoln GA. Pattern and localization of expression of vascular endothelial growth factor and its receptor flt-1 in the ovine pituitary gland: expression is independent of hypothalamic control. Mol Cell Endocrinol 134:91–100, 1997.
Banerjee SK, Sorkar DK, Westen AP, De Campbell A DR, Overexpression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumors angiogenesis. Carcinogenesis 18:1155–1161, 1997.
Sengjev DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, {FnDvorak} Am HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12:303–324, 1993.
Cheung N, Wang MP, Yuen ST, Leung SY, Chuz LP. Tissue specific expression patterns of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol 29:910–914, 1998.
Torimura T, Sata M, Uenu T, Kin M, Tsuji R, Suzaku K, Hashimoto O, Sugawara H, Tanikawa K. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 29:986–991, 1998.
Folkman J, Klagsbrum M. Angiogenic factors. Science 235:442–447, 1987.
Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327–336, 1991.
Yamamoto T, Nishiyama Y, Tsuji M, Saitoh Y, Funai H, Hirai T, Sugihara, A, Tsujimura T, Nakata Y, Ishiguro S, Terada N. Expression of vascular endothelial growth factor in normal pituitary cells and pituitary adenomas producing adenocorticotropic hormone. Endocrine Pathology 11, 1999 (In Press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lloyd, R.V., Scheithauer, B.W., Kuroki, T. et al. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10, 229–235 (1999). https://doi.org/10.1007/BF02738884
Issue Date:
DOI: https://doi.org/10.1007/BF02738884